Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation

Abstract excerpt

BACKGROUND: Cerebral cavernous malformation (CCM) is a hemorrhagic stroke disease affecting up to 0.5% of North Americans that has no approved nonsurgical treatment. A subset of patients have a hereditary form of the disease due primarily to loss-of-function mutations in KRIT1, CCM2, or PDCD10. We sought to identify known drugs that could be repurposed to treat CCM. METHODS AND RESULTS: We developed an unbiased...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Intracerebral and Subarachnoid Hemorrhage Research
• Share to Intracranial Aneurysms: Treatment and Complications
• Share to Vascular Malformations Diagnosis and Treatment